These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17076990)

  • 1. The incremental costs of recommended therapy versus real world therapy in type 2 diabetes patients.
    Crivera C; Suh DC; Huang ES; Cagliero E; Grant RW; Vo L; Shin HC; Meigs JB
    Curr Med Res Opin; 2006 Nov; 22(11):2301-11. PubMed ID: 17076990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
    Ramsdell JW; Braunstein SN; Stephens JM; Bell CF; Botteman MF; Devine ST
    Pharmacoeconomics; 2003; 21(11):819-37. PubMed ID: 12859222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan.
    Jarab AS; Alqudah SG; Mukattash TL; Shattat G; Al-Qirim T
    J Manag Care Pharm; 2012 Sep; 18(7):516-26. PubMed ID: 22971205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic.
    Hirsch JD; Bounthavong M; Arjmand A; Ha DR; Cadiz CL; Zimmerman A; Ourth H; Morreale AP; Edelman SV; Morello CM
    J Manag Care Spec Pharm; 2017 Mar; 23(3):318-326. PubMed ID: 28230459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing type 2 diabetes: going beyond glycemic control.
    Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
    J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Clinical Pharmacist-Led Comprehensive Medication Management on Chronic Disease State Goal Attainment in a Patient-Centered Medical Home.
    Prudencio J; Cutler T; Roberts S; Marin S; Wilson M
    J Manag Care Spec Pharm; 2018 May; 24(5):423-429. PubMed ID: 29694290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a program to improve diabetes care through intensified care management activities and diabetes medication copayment reduction.
    Kogut SJ; Johnson S; Higgins T; Quilliam B
    J Manag Care Pharm; 2012 May; 18(4):297-310. PubMed ID: 22548690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attainment of goals from national guidelines among persons with type 2 diabetes: a cohort study in an academic family medicine setting.
    Kirk JK; Huber KR; Clinch CR
    N C Med J; 2005; 66(6):415-9. PubMed ID: 16438097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study.
    Schleyer T; Hui S; Wang J; Zhang Z; Knapp K; Baker J; Chase M; Boggs R; Simpson RJ
    J Manag Care Spec Pharm; 2019 May; 25(5):544-554. PubMed ID: 31039062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
    Bibeau WS; Fu H; Taylor AD; Kwan AY
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
    Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
    PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actual versus projected cost avoidance for clinical pharmacy specialist-initiated medication conversions in a primary care setting in an integrated health system.
    Kroner BA; Billups SJ; Garrison KM; Lyman AE; Delate T
    J Manag Care Pharm; 2008 Mar; 14(2):155-63. PubMed ID: 18331117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in prescription medication costs after laparoscopic gastric bypass.
    Nguyen NT; Varela JE; Sabio A; Naim J; Stamos M; Wilson SE
    Am Surg; 2006 Oct; 72(10):853-6. PubMed ID: 17058720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of diabetes medication and cost of testing supplies in Saskatchewan, 2001.
    Johnson JA; Pohar SL; Secnik K; Yurgin N; Hirji Z
    BMC Health Serv Res; 2006 Dec; 6():159. PubMed ID: 17164006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular risk management in type 2 diabetes of more than 10-year duration: Results of Polish ARETAEUS2-Grupa Study.
    Leśniak W; Bała MM; Płaczkiewicz-Jankowska E; Topór-Mądry R; Jankowski M; Sieradzki J; Banasiak W;
    Cardiol J; 2015; 22(2):150-9. PubMed ID: 25299503
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.